Cell Rep. 2023 Jan 18. pii: S2211-1247(23)00024-4. [Epub ahead of print]42(1):
112013
Sarah Watson,
Collette A LaVigne,
Lin Xu,
Didier Surdez,
Joanna Cyrta,
Delia Calderon,
Matthew V Cannon,
Matthew R Kent,
Katherine M Silvius,
Jack P Kucinski,
Emma N Harrison,
Whitney Murchison,
Dinesh Rakheja,
Franck Tirode,
Olivier Delattre,
James F Amatruda,
Genevieve C Kendall.
Clinical sequencing efforts are rapidly identifying sarcoma gene fusions that lack functional validation. An example is the fusion of transcriptional coactivators, VGLL2-NCOA2, found in infantile rhabdomyosarcoma. To delineate VGLL2-NCOA2 tumorigenic mechanisms and identify therapeutic vulnerabilities, we implement a cross-species comparative oncology approach with zebrafish, mouse allograft, and patient samples. We find that VGLL2-NCOA2 is sufficient to generate mesenchymal tumors that display features of immature skeletal muscle and recapitulate the human disease. A subset of VGLL2-NCOA2 zebrafish tumors transcriptionally cluster with embryonic somitogenesis and identify VGLL2-NCOA2 developmental programs, including a RAS family GTPase, ARF6. In VGLL2-NCOA2 zebrafish, mouse, and patient tumors, ARF6 is highly expressed. ARF6 knockout suppresses VGLL2-NCOA2 oncogenic activity in cell culture, and, more broadly, ARF6 is overexpressed in adult and pediatric sarcomas. Our data indicate that VGLL2-NCOA2 is an oncogene that leverages developmental programs for tumorigenesis and that reactivation or persistence of ARF6 could represent a therapeutic opportunity.
Keywords: CP: Cancer; cross-species comparative oncology; developmental biology; functional genomics; fusion oncogene; pediatric cancer; rhabdomyosarcoma